Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "PPD"

15 News Found

Motorica India CRE programme enhances clinician training and patient-centric prosthetic care
Healthcare | April 23, 2026

Motorica India CRE programme enhances clinician training and patient-centric prosthetic care

Three-day programme focuses on advanced socket design, myoelectric technology and clinical skill development


Surya Brasil eyes India expansion after 30% US growth
News | February 23, 2026

Surya Brasil eyes India expansion after 30% US growth

The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner


Thermo Fisher and NVIDIA team up to supercharge labs with AI
Digitisation | January 14, 2026

Thermo Fisher and NVIDIA team up to supercharge labs with AI

Artificial intelligence coupled with laboratory automation will transform how scientific work is performed


Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site
News | August 22, 2025

Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site

The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities


Piramal Pharma Q1 FY25 net loss narrows
News | July 26, 2024

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24


Thermo Fisher Scientific to acquire CorEvitas for $912.5 million
News | July 10, 2023

Thermo Fisher Scientific to acquire CorEvitas for $912.5 million

Advances clinical research capabilities with leading regulatory grade registries platform


Emmes appoints Ching Tian as Chief Innovation Officer
People | December 16, 2022

Emmes appoints Ching Tian as Chief Innovation Officer

Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms


Merck presents positive results from phase 1/2 study evaluating V116
News | June 22, 2022

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019